Exelixis, Inc. (NASDAQ:EXEL) Director Jack L. Wyszomierski Sells 8,287 Shares

Exelixis, Inc. (NASDAQ:EXELGet Free Report) Director Jack L. Wyszomierski sold 8,287 shares of Exelixis stock in a transaction that occurred on Tuesday, June 4th. The shares were sold at an average price of $22.00, for a total value of $182,314.00. Following the sale, the director now directly owns 349,499 shares in the company, valued at $7,688,978. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Exelixis Price Performance

Shares of NASDAQ:EXEL opened at $21.88 on Friday. The stock has a market cap of $6.63 billion, a price-to-earnings ratio of 34.19, a P/E/G ratio of 0.54 and a beta of 0.56. The company has a 50 day moving average of $22.22 and a 200-day moving average of $22.30. Exelixis, Inc. has a one year low of $18.64 and a one year high of $24.34.

Exelixis (NASDAQ:EXELGet Free Report) last issued its earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.16). Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The business had revenue of $425.23 million for the quarter, compared to the consensus estimate of $461.04 million. During the same quarter in the previous year, the firm posted $0.12 EPS. The business’s revenue was up 4.0% on a year-over-year basis. Equities research analysts anticipate that Exelixis, Inc. will post 1.15 earnings per share for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Barclays lowered Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price target on the stock. in a research note on Thursday, April 11th. Stephens initiated coverage on shares of Exelixis in a report on Tuesday, May 14th. They issued an “equal weight” rating and a $23.00 target price on the stock. TD Cowen lifted their price target on shares of Exelixis from $25.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. StockNews.com cut shares of Exelixis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. Finally, William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Wednesday, May 1st. Seven research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Exelixis has an average rating of “Moderate Buy” and a consensus price target of $26.13.

View Our Latest Stock Report on EXEL

Hedge Funds Weigh In On Exelixis

Several institutional investors have recently modified their holdings of the stock. Fisher Asset Management LLC boosted its stake in Exelixis by 232.6% during the 4th quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 728 shares during the last quarter. Contravisory Investment Management Inc. acquired a new stake in shares of Exelixis during the fourth quarter worth $26,000. GAMMA Investing LLC bought a new stake in shares of Exelixis in the fourth quarter valued at about $27,000. Rise Advisors LLC acquired a new stake in shares of Exelixis in the first quarter valued at approximately $28,000. Finally, USA Financial Formulas boosted its holdings in Exelixis by 1,548.0% during the fourth quarter. USA Financial Formulas now owns 2,060 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 1,935 shares during the last quarter. 85.27% of the stock is currently owned by institutional investors and hedge funds.

About Exelixis

(Get Free Report)

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

Read More

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.